EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas

Jackson S Burton, Nicole C Foley, Neha Mehta-Shah

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.10.007 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Jackson S Burton und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral. Die Arbeit nennt 103 Literaturangaben. Gefördert von: Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although a rare subset of non-Hodgkin lymphomas, peripheral T-cell lymphomas (PTCL) account for a disproportionate proportion of patient mortality. Conventional therapies are derived from experience treating aggressive B-cell lymphomas and center around CHOP-based chemotherapy. However, due to the unique biology and diverse subtypes of PTCL, most patients fail to durably respond to this approach and 5-year survival is only 20% to 30%. There have been multiple attempts to improve outcomes for patients with PTCL. Among the more successful strategies are the use of consolidative autologous stem cell transplant, the augmentation of CHOP with etoposide (CHOEP), and the use of brentuximab vedotin in CD30-positive PTCL. Advances in the understanding of histology-specific biology has cultivated enthusiasm to evaluate hypomethylating agents, histone deacetylate inhibitors, and phosphoinositol-3-kinase inhibitors in the frontline setting. Improvements in monitoring disease response and prognostication including the use of cell-free DNA, mutational profiling, and interim PET/CT imaging are also on the horizon. For patients with acute T-cell leukemia/lymphoma, the use of mogamulizumab-based therapy in the frontline setting may lead to advances in care. The true impact of these new-era therapies will only be elucidated as clinical practices incorporate the rapidly changing evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, PeripheralHumansPositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinStem Cell Transplantation

Stichwörter der Autor:innen

Brentuximab vedotinHistone deacetylate inhibitorsPhosphoinositol-3-kinase inhibitors

Substanzen

Brentuximab Vedotin

Autor:innen und Institutionen

  • Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO.
  • Department of Medicine, Division of Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO. Electronic address: mehta-n@wustl.edu.

Förderung

  • Leukemia and Lymphoma Society

Zitieren

APA

Burton, J. S., Foley, N. C., & Mehta-Shah, N. (2024). SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.007

Vancouver

Burton JS, Foley NC, Mehta-Shah N. SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.007

BibTeX
@article{Burton2024,
  author = {Burton, Jackson S and Foley, Nicole C and Mehta-Shah, Neha},
  title = {SOHO State-of-the-Art Updates and Next Questions: Treatment for Newly Diagnosed Peripheral T-Cell Lymphomas},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.10.007}
}
Kostenlos starten →